Compare TG Therapeutics Inc (TGTX) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Uranium Energy Corp — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.36B), while Uranium Energy Corp trades at $11.64 (market cap $5.74B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals.
| TGTX | UEC | |
|---|---|---|
Market Cap | $8.36B | $5.74B |
Sector | Health | Energy |
52-Week High | $59.06 | $20.14 |
52-Week Low | $26.94 | $9.04 |
Enterprise Value | $8.57B | $5.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
UEC trades at $11.89, up 3.03% today, showing volatile momentum amid mixed technical signals. The stock faces fundamental challenges with negative profitability (-513.24% net margin) despite revenue of $66.84M in 2025, while analyst sentiment remains strongly bullish with 87.5% buy ratings. Recent news highlights institutional confidence, including BlackRock's $432.68M investment in August 2026, positioning UEC to benefit from nuclear energy tailwinds.
Outlook: High-risk, high-reward play on nuclear energy growth, but current financials show significant losses. Opportunities include sector tailwinds and institutional backing; risks involve persistent unprofitability and execution challenges in scaling operations. Investors should weigh speculative growth potential against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
